These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14679146)

  • 1. Investigational drug access taken to task in lawsuit against FDA.
    Randal J
    J Natl Cancer Inst; 2003 Dec; 95(24):1818-20. PubMed ID: 14679146
    [No Abstract]   [Full Text] [Related]  

  • 2. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
    Goozner M
    J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotech firm faces challenges from FDA, falling stock prices.
    Reynolds T
    J Natl Cancer Inst; 2002 Mar; 94(5):326-8. PubMed ID: 11880468
    [No Abstract]   [Full Text] [Related]  

  • 5. "Right to Try" Laws: The Gap between Experts and Advocates.
    Dresser R
    Hastings Cent Rep; 2015; 45(3):9-10. PubMed ID: 25944200
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 7. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 8. Experimental drugs on trial.
    Benderly BL
    Sci Am; 2007 Oct; 297(4):92-9. PubMed ID: 17926760
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient group seeks overhaul of FDA clinical trial system in court.
    Hede K
    J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
    [No Abstract]   [Full Text] [Related]  

  • 10. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demand grows for early access to promising cancer drugs.
    Baldwin J
    J Natl Cancer Inst; 2002 Nov; 94(22):1668-70. PubMed ID: 12441318
    [No Abstract]   [Full Text] [Related]  

  • 12. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.
    Cancer Biol Ther; 2006 Apr; 5(4):340-2. PubMed ID: 16808060
    [No Abstract]   [Full Text] [Related]  

  • 13. Promising drug is victim of bad business.
    Dove A
    Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA revamps committee conflict-of-interest rules.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Oct; 98(19):1354-5. PubMed ID: 17018777
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigational drugs and the constitution.
    Dresser R
    Hastings Cent Rep; 2006; 36(6):9-10. PubMed ID: 17278864
    [No Abstract]   [Full Text] [Related]  

  • 16. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 17. Like raising a child.
    Berger MS
    J Clin Oncol; 2012 Apr; 30(10):1140-1. PubMed ID: 22253464
    [No Abstract]   [Full Text] [Related]  

  • 18. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Demand grows for early access to promising cancer drugs.
    Genève J
    J Natl Cancer Inst; 2003 Mar; 95(6):492. PubMed ID: 12644549
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA accelerated approval benefits glioblastoma.
    Cloughesy T
    Lancet Oncol; 2010 Dec; 11(12):1120. PubMed ID: 21126686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.